Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0472 as Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors
NCT05853367Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2023
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of MK-0472 in solid tumor (3 arms), sponsored by Merck & Co. Primary endpoints: Dose Limiting Toxicity at 21 days, Adverse Events at 60 months and 1 more. Started Jul 2023; status: active, not recruiting.
02
Drugs
MK-0472
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05853367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05853367.